

Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes From an 11-year Retrospective Observational Cohort in Northern Sweden

Martin Plymoth,^{1,2} Robert Lundqvist,³ Anders Nystedt,⁴ Anders Sjöstedt,⁵ and Tomas N. Gustafsson¹

¹Department of Clinical Microbiology, Sunderby Research Unit, Umeå University, Umeå, Sweden; ²Department of Infectious Diseases, Westmead Hospital, Sydney, New South Wales, Australia; ³Department of Public Health and Clinical Medicine, Sunderby Research Unit, Umeå University, Umeå, Sweden; ⁴Department of Communicable Disease Control, County Council of Norrbotten, Luleå, Sweden; and ⁵Department of Clinical Microbiology, Umeå University, Umeå, Sweden

Background. Tularemia is an important reemerging disease with a multimodal transmission pattern. Treatment outcomes of current recommended antibiotic regimens (including ciprofloxacin and doxycycline) remain unclear. In this retrospective cohort study, we report clinical, laboratory, geographical, and treatment outcomes of laboratory-confirmed tularemia cases over an 11-year period in Northern Sweden.

Methods. Data from reported tularemia cases (aged >10 years at time of study) in Norrbotten county between 2011 and 2021 were collected through review of electronic medical records and participant questionnaires; 415 of 784 accepted participation (52.9%). Of these, 327 were laboratory-confirmed cases (serology and/or polymerase chain reaction). A multivariable logistic regression model was used to investigate variables associated with retreatment.

Results. Median age of participants was 54 years (interquartile range [IQR], 41.5–65) and 49.2% were female. Although ulceroglandular tularemia was the predominant form (n = 215, 65.7%), there were several cases of pulmonary tularemia (n = 40; 12.2%). Inflammatory markers were largely nonspecific, with monocytosis frequently observed (n = 36/75; 48%). Tularemia was often misdiagnosed on presentation (n = 158, 48.3%), with 65 (19.9%) receiving initial inappropriate antibiotics and 102 (31.2%) retreated. Persistent lymphadenopathy was infrequent (n = 22, 6.7%), with 10 undergoing surgical interventions. In multivariable analysis of variables associated with retreatment, we highlight differences in time until receiving appropriate antibiotics (8 [IQR, 3.25–20.75] vs 7 [IQR, 4–11.25] days; adjusted *P* = .076), and doxycycline-based treatment regimen (vs ciprofloxacin; adjusted *P* = .084), although this was not significant after correction for multiple comparisons.

Conclusions. We comprehensively summarize clinical, laboratory, and treatment outcomes of type B tularemia. Targeting tularemia requires clinical awareness, early diagnosis, and timely commencement of treatment for an appropriate duration.

Keywords. *Francisella tularensis*; doxycycline; ciprofloxacin; treatment; outcome.

Tularemia is a reemerging zoonotic disease present in most countries in the Northern Hemisphere [1, 2]. Outbreaks of tularemia caused by the bacterium *Francisella tularensis* subsp. *holarctica* (“type B”) have occurred at irregular intervals in the northern parts of Sweden since first described in the country in 1931 [3, 4]. Although there is notable annual fluctuation, there has been an increasing trend in the number of cases seen across Sweden and the entire European Union over the latest 5-year period (2017–2021) [5, 6]. Increasing frequency of

outbreaks in middle and southern parts of Sweden suggests tularemia is a reemerging infectious disease complexly linked with climate change [6–14].

Zoonotic, waterborne, airborne, and vector (primarily mosquito)-borne outbreaks of the disease have important health-related and socioeconomic burden on individuals and society through prolonged illness, absence from work, and healthcare costs [6].

Manifestations of the disease vary depending on inoculation dose, type of exposure (oral, ocular, pulmonary, cutaneous), and geographical location (type A in North America vs type B globally), with the latter causing debilitating symptoms, but rarely resulting in lethality [4, 15, 16].

Recommended treatment regimens for tularemia include aminoglycosides (streptomycin and gentamicin), quinolones (ciprofloxacin), and tetracyclines (doxycycline), but knowledge of their in vivo effectiveness remains scarce [6, 17–20]. Based on limited available evidence, the World Health Organization recommends treatment with ciprofloxacin 500 mg twice daily

Received 17 November 2023; editorial decision 28 January 2024; published online 23 February 2024

Correspondence: T. N. Gustafsson, Department of Clinical Microbiology, Umeå University, SE-90185, Umeå, Sweden (tomas.gustafsson@umu.se).

Clinical Infectious Diseases® 2024;78(5):1222–31

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. <https://doi.org/10.1093/cid/ciae098>

for 10 days, or doxycycline 100 mg twice daily for 14 days for milder disease in adults, but comparisons of treatment outcomes are limited to small case series [18, 21, 22].

In this study, we comprehensively investigated clinical, microbiological, laboratory, and treatment outcomes in a cohort of tularemia cases in northern Sweden, which includes the second (2019) and third (2015) largest outbreaks recorded in Sweden.

METHODS

Study Setting

This study was performed in Norrbotten County, the largest (98 245 km²) and northernmost county in Sweden, with a sparse population of approximately 250 000 [23].

Study Design and Procedure

This is a retrospective cohort study involving electronic medical record (EMR) review of tularemia cases in Norrbotten in combination with a targeted questionnaire to further explore clinical details. Cases were identified via the National Infection Control database (SmiNet). Inclusion criteria were: (1) diagnosis 2011–2021; (2) alive at time of study; (3) available contact details; and (4) age ≥ 10 years at time of study consent. Exclusion criteria were: (1) nonresponse/declined study participation; (2) unavailable EMR documentation; (3) improbable clinical diagnosis; or (4) not meeting World Health Organization presumptive or confirmed tularemia case definition [18].

Eligible participants were sent a letter containing a questionnaire, consent form, study information sheet, and web link to a secure survey platform (EvaSysV8.1, Region Norrbotten). Nonrespondents were sent notifying mobile text messages and a second paper questionnaire.

Serology and Microbiology

Serological analysis was performed at the regional clinical microbiology laboratory at Sunderby hospital, Luleå, Sweden, using an immunochromatographic rapid test (VIRapid, Vircell, Granada, Spain) [24]; and the national reference laboratory for tularemia at Umeå University hospital, Umeå, Sweden, using a validated in-house enzyme-linked immunosorbent assay, together with polymerase chain reaction (PCR) and cultures [25].

Statistical Analysis

Data were collected from the regional EMR (VAS 49.0, Region Norrbotten), including documentation from general practitioners (GPs), hospitals, and specialist clinics. Integrated electronic prescriptions and microbiological data were reviewed. Geographical information of reported site of infection was mapped using Epi Info 7.2.5 (Centre for Disease Control). Statistical analysis was performed in SPSS 28.0 (IBM). Statistical methods included logistic regression (categorical variables) and Mann-Whitney *U* test (continuous and ordinal

variables) for univariate analysis; a multivariable logistic regression model using a stepwise backwards elimination protocol (Supplementary Table 1) [26]. Holm-Šidák correction was applied, with a corrected *P* value $< .05$ considered significant.

Ethics

Ethics committee approval was obtained from The Swedish Ethical Review Authority (Dnr 2020-04411, 2021-02953) and Norrbotten County Research Council (Dnr 01690-2020). All study participants received written age-appropriate information about the study and provided written informed consent. Additionally, parental consent was obtained for individuals aged < 15 years.

RESULTS

Study Participants

In total, 830 cases of suspected or confirmed tularemia were reported to the Department of Communicable Disease Control, Norrbotten County, Sweden, between 1 January 2011 and 31 December 2021 (incidence, 30.1 per 100 000 per year). Three cases of tularemia reinfection were reported, all without laboratory confirmation. Overall, there were 441 questionnaire respondents between 30 December 2020 and 16 October 2022 (56.3% response rate), with 26 declining study participation. A further 88 of 415 were excluded after EMR review (Figure 1).

Study participants had a median age of 54 years at time of diagnosis (interquartile range [IQR], 46–65) and equal gender distribution (Table 1). Compared with all reported adult cases (aged ≥ 18 years), adult study participants (respondents) were older (median, 55 [IQR, 45–65] vs 53 [IQR, 40–65] years; $P = .034$) and less likely to be male (50.7% vs 57.8%; $P = .049$), but did not vary with regard to time since diagnosis (median, 6 [IQR, 6–9] vs 6 [IQR, 6–9] years; $P = .088$).

Geographical distribution (Figure 2) showed predominance of tularemia cases in coastal municipalities, as well as high incidence (> 80 per 100 000 inhabitants) in certain highland areas popular among tourists, with a high density of lakes and waterways.

Microbiological Analyses

Of 327 laboratory-confirmed cases, 298/311 (95.8%) had at least 1 positive serology, whereas 13/311 had 1 negative serology taken early on, combined with positive PCR and/or culture (Table 1). Overall, 114 (36.7%) had a documented seroconversion or significant rise in antibody titer [25]. *F. tularensis* PCR was positive in 43/43 (100%) samples from peripheral sites, 1/1 (100%) transbronchial needle aspirates, and 0/2 (0%) cerebrospinal fluid samples. *F. tularensis* ($n = 18$) was cultured from peripheral swabs ($n = 13$), blood ($n = 3$), pleural fluid ($n = 1$), and lymph node biopsy ($n = 1$).




Figure 1. Study method and inclusion of participants. EMR, electronic medical record. ^aLack of electronic medical record documentation ($n = 15$); confirmed false-positive tularemia tests ($n = 2$; $\times 1$ false-positive rapid test, $\times 1$ false-positive PCR); misdiagnosis (later confirmed as mycoplasma infection via PCR; $n = 1$); incidental positive serology without evident clinical symptoms of tularemia infection ($n = 5$); age <10 y at time of survey ($n = 2$). ^bClinical diagnosis of tularemia without a positive tularemia serology, culture, and/or PCR and were therefore excluded from further analysis (of these, 15 had a single negative serology result and 1 had a negative PCR result). PCR, polymerase chain reaction.

Clinical Manifestations

Visible skin ulceration and regional lymphadenopathy were seen among 215 (65.7%) participants (ulceroglandular tularemia), whereas 34 (10.4%) had isolated tender and enlarged lymph nodes (glandular tularemia; Table 1). Lymphadenopathy was located in the lower extremities in 156 (62.7%), the upper extremities (axilla or chest) in 39 (15.7%), the head/neck region in 41 (16.5%), and in an unspecified location in 13 (5.2%) cases. A single case of oculoglandular tularemia was reported. Eight participants reported a transient pharyngitis, but symptoms were otherwise not consistent with oropharyngeal tularemia. Twenty-four (7.3%) participants had persistent fever without localized symptoms, suggestive of typhoidal tularemia. Other symptoms included diarrhea and/or vomiting ($n = 17$; 5.2%)

and headache ($n = 84$; 25.7%). Onset of primary lymphadenopathy and/or skin lesion and fever generally occurred within the same time frame (median, 0 days; IQR, -2 to $+1$ days).

Respiratory symptoms (cough, shortness of breath, pleuritic chest pain) were described among 59 (18.0%) participants. Among these who had chest radiograph imaging, 25/40 (62.5%) had confirmed infiltrates and 5/40 (12.5%) cases had atypical imaging findings. Fifteen cases had confirmed infiltrates on computed tomography (CT) scans, with 14 scans reporting nodular infiltrates (5 involving multiple lobes), 4 suspected pulmonary abscesses, 8 enlarged thoracic lymph nodes >10 mm, and 4 necrotic lymph nodes. Six CT reports were highly suspicious for malignancy, with 3 undergoing positron emission tomography/CT scanning, and 1 CT-guided lung

Table 1. Demographic, Microbiological, Clinical, and Laboratory Manifestations of Laboratory-Diagnosed Tularemia Cases and Associated Abnormal Values (n = 327)

	Laboratory-Diagnosed Tularemia Cases (n = 327)	Values Outside Laboratory Reference Range (%)
Age (y)	54 (IQR, 41.5–65)	
10–19	24 (7.3%)	
20–39	50 (15.3%)	
40–59	128 (39.1%)	
60–79	120 (36.7%)	
≥80	5 (1.5%)	
Gender		
Male	166 (50.7%)	
Female	161 (49.2%)	
Immunosuppression		
Mildly immunocompromised ^a	3 (0.9%)	
Severely immunocompromised ^b	6 (1.8%)	
Diabetes mellitus	1 (type 1, 0.3%); 17 (type 2, 5.2%)	
Pregnant at time of diagnosis	0 (0%)	
Clinical manifestations		
Ulceroglandular	215 (65.7%)	
Glandular	34 (10.4%)	
Pulmonary	40 (12.2%)	
Typhoidal	24 (7.3%)	
Oculoglandular	1 (0.3%)	
Oropharyngeal	0 (0%)	
Undifferentiated ^c	23 (7.0%)	
Microbiological diagnosis		
Positive <i>F. tularensis</i> serology titer (n = 311)	298 (95.8%)	
Seroconversion or significant rise in titer	114 (36.7%)	
PCR positive (n = 46)	44 (95.6%)	
Culture grown <i>F. tularensis</i>	18 (39.1%)	
Laboratory findings		
CRP (mg/L; n = 288)	60 (30–108)	
Leukocytes (×10 ⁶ cells/mL; n = 198) ^d	7.6 (6.2–9.3)	>8.8: 58 (29.3%)
Neutrophils (×10 ⁶ cells/mL; n = 71)	5.1 (3.6–6.2)	>6.1: 21 (29.6%)
Lymphocytes c (×10 ⁶ cells/mL; n = 76)	1.6 (1.1–2.3)	<1.1: 16 (21%) > 3.5: 3 (3.9%)
Monocytes c (×10 ⁶ cells/mL; n = 75)	0.7 (0.5–1.0)	>0.8: 36 (48.0%)
Eosinophils (×10 ⁶ cells/mL; n = 74)	0.09 (0.080–0.090)	>0.5: 0 (0%)
Basophils (×10 ⁶ cells/mL; n = 73)	0.03 (0.010–0.050)	>0.1: 2 (2.7%)
Hemoglobin (g/dL; n = 212)	137 (128–146)	<120 (female) or <130 (male): 40 (18.9%)
Platelets (×10 ⁶ /mL; n = 204)	216 (168–300)	<150: 28 (13.7%) > 300: 50 (24.5%)
Procalcitonin (ng/mL; n = 17)	0.21 (0.13–0.34)	>0.1: 15 (88.2%) > 0.25: 6 (35.3%)
Urine analysis (n = 33)		
Hematuria	18 (54.5%)	Trace: 4 (12.1%) 25: 4 (12.1%) 80: 8 (24.2%) 200: 2 (6%)
Proteinuria	17 (51.5%)	Trace: 1 (3%) 0.3 (+): 10 (30.3%) 1.0 (++) 6 (18.2%)
Pyuria	7 (21.2%)	15: 5 (15.2%) 70: 1 500: 1

Abbreviations: CRP, C-reactive peptide; *F. tularensis*, *Francisella tularensis*; PCR, polymerase chain reaction.

^aLow-dose corticosteroids (equivalent to <20 mg prednisolone; n = 2); methotrexate (≤0.4 mg/kg/week; n = 1).

^bInfliximab and methotrexate (n = 2); Etanercept 50 mg and methotrexate 15 mg weekly (n = 1); golimumab monthly and methotrexate 15 mg weekly (n = 1); cyclosporine (n = 1); etanercept and sulfasalazine 500 mg 4 times per day (n = 1).

^cTwelve participants (3.7%) had ulcers without documented lymphadenopathy and a further 11 (3.4%) had nonspecific mild symptoms.

^dParticipants aged <18 years were excluded because of alternative cutoff values.




Figure 2. Geographical distribution and epidemiological incidence of tularemia cases at municipality level in Norrbotten County over 11 y between 2011 and 2021 (n = 243). Incidence calculated using total number of reported cases (N = 830). Blue dots indicate self-reported location of exposure/illness by individual cases. Number in blue dots indicate cumulative number of cases in area.

biopsy. Fourteen (93.3%) cases underwent repeat CT of the chest with partial or complete resolution of infiltrates/lymph nodes. No malignancy was identified during follow-up.

Secondary skin manifestations separate from the primary ulcer site and lymph node were self-reported among 44 (13.5%) participants. Rashes were documented in 34 (10.4%) cases, with characteristics reported in 16 cases. Of these, 2 were erythema nodosum, 6 vesicular, 2 pustular, 4 macular, and 2 papular. Sites of secondary rashes were lower limbs (n = 16; 61.9%), upper extremities (n = 12; 57.1%), trunk and/or back (n = 7; 33.3%), and/or head and/or neck (n = 6; 28.6%). Palmar involvement was described in a single case, whereas no mucosal involvement was reported. Median time until onset of rash was 10 days from symptom onset (n = 11; range, 4–20 days). In 19 cases, rashes occurred after initiation of antibiotic treatment (median, 3; range, 0–5 days), whereas 4 developed a rash before starting treatment.

Participants waited a median of 4 days (IQR, 3–7 days) from symptom onset until seeking healthcare. First point of contact were GPs (n = 229; 70.0%), after-hours GPs (n = 48; 14.7%), emergency departments (n = 40; 12.2%), or specialist clinics (n = 9; 2.75%); 227 (69.4%) had subsequent follow-up.

Fifty-two (15.9%) participants required hospital admission, with indications including suspected severe illness (n = 16; 30.8%) and/or investigation of unknown fever (n = 43; 82.7%). Admitting teams included internal/respiratory medicine (n = 26; 50%), infectious diseases (n = 19; 36.5%), pediatrics (n = 2; 3.8%), and otorhinology (n = 3; 5.8%).

An initial alternative presumptive diagnosis was frequent at presentation (n = 158; 48.3%), including unspecified viral infection (n = 51; 13.1%), bacterial skin/soft-tissue infection (n = 31; 9.5%), bacterial respiratory infection (n = 16; 4.9%), Puumala virus infection (n = 11; 3.4%), undifferentiated fever/sepsis (n = 13; 3.4%), urinary tract infection (n = 9; 2.8%), other specified infections (8; 1.8%), meningitis (n = 5; 1.5%), eczema/urticaria (n = 3; 0.9%), thromboembolic events (n = 3; 0.9%), or acute surgical pathology (n = 2; 0.6%).

Of 230 participants with temperature recorded at time of the first healthcare visit, 137 (59.6%) had a temperature $\geq 38.0^{\circ}\text{C}$. Median temperature was 38.3°C (IQR, $37.5\text{--}39.0$). Participants presenting later had a lower median initial temperature (Figure 3A). Median self-reported duration of fever was 5 days (IQR, 4–10).




Figure 3. Initial recorded (A) temperature (°C) and (B) CRP and at time from onset of tularemia symptoms ($n = 289$). Box diagram denotes median, interquartile range, range (extreme values not included). Line denotes mean values. CRP, C-reactive protein.

Laboratory Manifestations

Laboratory data (Table 1) were available for most patients because of capillary point-of-care testing in all primary care facilities. Among 289 (88.4%) participants who had an initial C-reactive protein (CRP) recorded, median CRP was highest on days 7 through 9 after symptom onset (78 mg/L; IQR, 40–133), and lower among participants who presented later, suggesting a spontaneous reduction over time and/or milder illness (Figure 3B).

Leukocyte counts remained within normal limits for most participants ($\leq 8.8 \times 10^6$ cells/mL; $n = 140$; 70.7%), whereas

monocytosis ($>0.8 \times 10^6$ cells/mL) was present among 36 cases (48.0%). Procalcitonin was mildly elevated (>0.1 ng/mL) among most cases ($n = 15$; 88.2%), whereas few had levels above 0.25 ng/mL ($n = 6$; 35.3%).

Treatment Outcomes

A total of 321 (98.2%) participants received antibiotic treatment, which was started a median of 5 days after onset of symptoms (IQR, 3–9 days). Median time until appropriate antibiotic regimen (defined as a quinolone, tetracycline, or aminoglycoside) was 7 days (IQR, 4–14 days).




Figure 4. Antibiotic treatment (and retreatment) pathways for laboratory-confirmed tularemia cases ($n = 327$). Rectangles represents retreatment. ^aIncluding 2 cases combined with 5 d of tobramycin (not requiring further retreatment). ^bOther treatments included: rifampicin/isoniazid/pyrazinamide/ethambutol for tuberculosis regimen ($n = 1$), and erythromycin ($n = 1$). ^cIn combination with vancomycin ($n = 1$), ciprofloxacin ($n = 2$).

Initial antibiotic treatment (Figure 4) was most often ciprofloxacin ($n = 223$; 68.2%). Twenty-five participants (7.6%) had a previous documented allergy to antibiotics, predominantly beta-lactams ($n = 20$). Overall, 71 (21.7%) participants did not receive an appropriate first-line antibiotic, of which 6 (1.8%) received no documented antibiotic treatment.

Retreatment

A second antibiotic agent was given to 102 (31.2%) of participants. Of these, 62 (60.7%) had received an inappropriate first-line antibiotic (Figure 4).

Among participants initially treated with ciprofloxacin, 27 (12.1%) received retreatment. Of these, 7 (25.9%) had <10 days of initial treatment. Reported causes for retreatment were suspected bacterial superinfection ($n = 2$), adverse drug reaction ($n = 8$), or suspected treatment failure ($n = 17$; nonmutually exclusive: persistent lymphadenitis [$n = 9$], persistent/recurrent

fevers [$n = 3$], persistent arthralgia/suspected reactive arthritis [$n = 2$], persistent cough [$n = 2$], peri-/postinfectious lethargy [$n = 2$], relapsing myopericarditis [$n = 1$]).

Among participants receiving initial treatment with doxycycline, 13 (39.4%) were retreated. Four (30.8%) had received subtherapeutic doses, and 10 (76.9%) were medicated for <14 days. Among those successfully treated with doxycycline, only 1 (5%) had subtherapeutic dosing, whereas 5 (25%) had treatment <14 days. Reported causes for retreatment were optimization of antibiotics after tularemia diagnosis ($n = 2$), adverse drug reaction ($n = 2$), and suspected treatment failure ($n = 9$; peri-/postinfectious lethargy [$n = 4$], persistent lymphadenitis [$n = 4$]; persistent/recurrent fevers [$n = 3$], persistent cough [$n = 3$]).

Persistent lymphadenopathy (after 1 course of appropriate antibiotics) was present among 22 cases (6.7%); with 6 (27.3%) having spontaneously draining suppurative lymph

Table 2. Comparison of Characteristics of Participants With Completed Treatment After Appropriate Antibiotic Regimens vs Those Requiring Further Treatment Courses

	Completed Treatment After Appropriate Antibiotic Regimen (n = 267) ^a	Retreatment After Appropriate Antibiotic Regimen (n = 45) ^b	Missing Values	Univariate P Value	Multivariable P Value (adjusted)
Gender				.506	
Male	133 (49.8%)	25 (56.5%)			
Female	134 (50.2%)	20 (43.5%)			
Age (y)	54 (IQR, 40–65)	57 (IQR, 47–66)		.156	.270 (.270)
CRP (mg/L)	55 (IQR, 30–102)	67 (29.5–120.5)	37 (11.9%)	.650	
Leukocytes (×10 ⁶ cells/mL)	7.50 (IQR, 6.20–9.05)	7.60 (IQR, 6.25–9.38)	104 (33.3%)	.833	
Days until seeking healthcare	4 (IQR, 3–7)	3 (IQR, 2–5.75)	13 (4.2%)	.045	
Days until appropriate antibiotic	7 (IQR, 4–11.25)	8 (IQR, 3.25–20.75)	13 (4.2%)	.210	.026 (0.076)
Respiratory symptoms	47 (17.5%)	8 (17.8%)		.928	
Year of treatment				.518	
Nonepidemic year	43 (16.1%)	9 (20.0%)			
Epidemic year (2012, 2015, 2019)	224 (83.9%)	36 (80.0%)			
Initial appropriate regimen				.024	.043 (.084)
Ciprofloxacin	240 (89.9%)	35 (77.8%)			
Doxycycline	27 (10.1%)	10 (22.2%)			
Antibiotic regimen with appropriate dose and duration			18 (5.8%)	.500	[.524] ^c
Ciprofloxacin ≥500 mg twice daily ≥10 d	239 (89.5%)	27 (60.0%)			
Doxycycline ≥100 mg twice daily ≥14 d	24 (9.0%)	4 (8.8%)			
Immunosuppression	7 (2.6%)	1 (2.2%)		.876	

Logistic regression for categorical variables. Mann-Whitney *U* test for ordinal and continuous variables. Data reported in absolute numbers and percentages (in brackets), or median and interquartile range, as specified. Significance in multivariable analysis after Holm-Šidák correction applied for adjusted *P* values is displayed in brackets.

Abbreviations: CRP, C-reactive protein; IQR, interquartile range.

^aDefined as regimen containing ciprofloxacin, aminoglycoside, or doxycycline, as per the World Health Organization.

^bRetreatment despite a course of ciprofloxacin or doxycycline, individuals with “optimization” of antibiotics after diagnosis (n = 2) or adverse drug reactions requiring treatment with alternative regimen (n = 11) were excluded.

^cValue included as alternative to “initial appropriate regimen” in multivariable analysis and not part of formal multivariable model.

nodes, 6 (27.3%) receiving fine-needle aspiration, and 4 (18.2%) incision and drainage. Three aspirates were *F. tularensis* PCR positive and 1 was culture positive; however, not all aspirates were sent for analysis.

Multivariable Analysis of Treatment Outcomes

Participants who experienced treatment failure after receiving an appropriate antibiotic regimen were compared with those who had successful treatment (Table 2). Variables were analyzed using multivariable analysis after correction for multiple comparisons and included time until receiving appropriate antibiotics (8 [IQR, 3.25–20.75] vs 7 [IQR, 4–11.25] days; adjusted *P* = .076), doxycycline-based treatment regimen (vs ciprofloxacin; adjusted *P* = .084), and participant age (years; adjusted *P* = .270). Thus, no significant correlations were identified.

DISCUSSION

In this retrospective cohort study of 327 tularemia cases in northern Sweden, we demonstrate that tularemia is a multifaceted disease with a multitude of differential diagnoses and wide range of clinical manifestations, including prolonged suppurative lymphadenitis and atypical respiratory infection. We further describe successful treatment outcomes among individuals receiving early

treatment with ciprofloxacin and doxycycline and highlight time until appropriate treatment as a potential cause for requiring retreatment, as previously noted [27].

Our cohort had similar demographics to previous studies performed in northern Europe [3, 9, 11, 28–31] and identified men and women aged 40 to 60 years as having the highest burden of tularemia, although there was high prevalence of infection throughout all age groups. Our data support ulceroglandular tularemia transmitted by mosquitos as the predominant clinical form in this geographical region [6, 31], pulmonary tularemia as an important cause of pneumonia, and atypical disease often misdiagnosed as malignancy and/or tuberculosis [9, 32]. Immunosuppression was infrequent in our cohort (n = 8), with 4 cases admitted to the hospital, including 1 developing pulmonary tularemia and 2 cases with *F. tularensis* septicemia.

Our findings show secondary skin manifestations in approximately 15% of cases, consistent with previous studies [9, 33–35]. Children aged 10 to 15 years appeared to have frequent skin involvement (54.5%), as previously described [36]. Interestingly, secondary skin manifestations appeared in close relation to commencing appropriate antibiotics, and one could speculate about a correlation between the 2. We highlight that limited knowledge about these reactions can lead to potentially inappropriate allergy labeling, as evidenced by our cohort.

Reported laboratory values in our cohort identified CRP (50–150 mg/L in 45.3%), procalcitonin (>0.1 ng/mL in 88.2%; <0.5 ng/mL in 94.1%) and monocytes (>0.8 × 10⁶ cells/mL in 48.0%) as nonspecific markers for tularemia infection in the context of high clinical suspicion [16]. Previous studies have predominantly reported normal differential counts in type B tularemia, with monocytosis >0.95 × 10⁶ cells/mL present in 4% of cases compared with 30.6% in our cohort [9, 37]. Leukocyte differential count is not routinely performed in primary care settings in Sweden. Perhaps wider implementation could help guide diagnosis of atypical manifestations of tularemia.

Chronic suppurative lymphadenitis has previously been described in up to 30% of patients with ulceroglandular and glandular tularemia [1, 9]. We describe chronic suppuration in 8.8% of cases, often leading to surgical intervention and/or retreatment with multiple courses of antibiotics. Interestingly, among PCR-positive cases, culture negativity was associated with longer time since symptom onset (median, 10.5 days; IQR, 6.5–23.0 vs 6 days; IQR, 4.75–8.5; *P* = .029). It remains unclear whether replicating bacteria are present in the ulcer after completed treatment or whether persistent lymphadenitis is primarily driven by an inflammatory response, as highlighted by few PCR-positive cases after aspiration and only a single culture positive [38]. Rates of incision and drainage appear to be lower in our cohort than in studies from France (27%) and the United States (19%) [13, 39], perhaps potentially related to shorter time until institution of appropriate antibiotic treatment. Even higher rates (60%) have been reported in pediatric populations [40]. The clinical value of prolonged antibiotic treatment in drained suppurative lymphadenitis remains unclear and will require further studies, potentially stratified by PCR status and/or culture.

Our cohort appears to have lower retreatment rates after appropriate antibiotic regimens than previous studies (16.8% vs 38.6%) [13]. This could be explained by the short duration to receiving appropriate therapy, as observed in another Swedish study with 95.3% successful treatment rate after initiating therapy early (median, 3 days from symptom onset) [19]. We further show successful treatment in 3 of 4 (75%) of cases treated with moxifloxacin as a first- or second-line antitularmia agent, as supported by previous in vitro studies [17]. As previously described [6, 17], treatment with beta-lactams or clindamycin appears ineffective.

Comparisons between ciprofloxacin and doxycycline for treatment of tularemia have previously been limited by sample size [13, 18, 20, 22, 39]. In our cohort, we show a multivariable trend toward requiring retreatment in those receiving doxycycline compared with ciprofloxacin (adjusted *P* = .076); however, when accounting for appropriate dosing and duration of antibiotic therapy, there was no significant difference between groups (14.2% vs 10.2%; *P* = .524). Although this is consistent with previous studies showing that shorter treatment periods

are associated with relapse [22], our study is likely underpowered for assessment of this outcome.

Interestingly, we observed a broad range of differential diagnoses among clinicians, leading to 19.9% of participants receiving empiric antibiotics ineffective against tularemia. Higher rates were observed during nonepidemic years, suggesting that improved awareness and high clinical suspicion is required among clinicians to promote overall outcomes given that initial serological results can be negative [9].

No deaths were recorded in our cohort, and only 3 deaths were reported to the Swedish Cause of Death Register between 1997 and 2022, suggesting that, although type B tularemia can cause serious morbidity, it is rarely fatal.

Our study was limited by its retrospective design. Despite being 1 of the largest descriptive studies of clinical outcomes in tularemia, the sample size limited statistical analysis. Antibiotic treatment outcomes are difficult to interpret in those receiving retreatment because cases often received overlapping antibiotic regimens. The addition of a questionnaire to study participants improved the quality of clinical data by assessing long-term outcomes, but because of the long time between infection and time of survey in some cases, recall bias and limited memory could have influenced these results. Respondents were slightly older and more likely to be female compared with overall reported cases, introducing a selection bias that could have skewed the results. While our results should be generally applicable to type B tularemia in northern Europe, the level of relevance remains unclear in settings where alternative clinical and microbiological forms dominate.

CONCLUSION

In conclusion, we comprehensively summarize clinical, laboratory, and treatment outcomes of type B tularemia. Targeting tularemia remains challenging because of its multifaceted presentation with a wide range of differential diagnosis and unclear optimal treatment regimens. We believe the present study can provide guidance regarding targeted treatment and highlight areas for future research. Ideally, a randomized controlled trial to evaluate effectiveness of antibiotic therapies, as well as the possible need for prolonged antibiotic treatment in suppurative lymphadenitis, should be conducted to improve clinical outcomes.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. Conceptualization: T. N. G., M. P., A. S., R. L., and A. N. Investigation: M. P., T. N. G., and R. L. Formal analysis: M. P., T. N. G., and R. L. Writing – Original Draft: M. P. and T. N. G. Writing

– Review & Editing: T. N. G., A. S., M. P., A. N., and R. L. Supervision: T. N. G.

Acknowledgments. The authors thank the study participants for their valuable contributions.

Data Availability. Data not publicly available.

Financial support. This work was supported by generous funding from the County Council of Norrbotten (NLL-933177 to T. N. G.); Umeå University through a regional agreement with the County Council of Norrbotten (ALF Universitets-ST to T. N. G.); and from County Council of Västerbotten (RV-966950 and RV-939171 to A. S.).

Potential conflicts of interest. T. N. G. serves on the scientific advisory board for Thioredoxin Systems AB. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. *Ann N Y Acad Sci* **2007**; 1105:1–29.
2. Yeni DK, Büyük F, Ashraf A, Shah M. Tularemia: a re-emerging tick-borne infectious disease. *Folia Microbiol* **2021**; 66:1–14.
3. Tärnvik A, Sandström G, Sjöstedt A. Epidemiological analysis of tularemia in Sweden 1931–1993. *FEMS Immunol Med Microbiol* **1996**; 13:201–4.
4. Johansson A, Farlow J, Larsson P, et al. Worldwide genetic relationships among *Francisella tularensis* isolates determined by multiple-locus variable-number tandem repeat analysis. *J Bacteriol* **2004**; 186:5808–18.
5. European Centre for Disease Prevention and Control. The European Union One Health 2021 zoonoses report. *EFSA J* **2022**; 20:e07666.
6. Maurin M, Gyuranecz M. Tularaemia: clinical aspects in Europe. *Lancet Infect Dis* **2016**; 16:113–24.
7. Dryselius R, Hjertqvist M, Mäkitalo S, et al. Large outbreak of tularaemia, central Sweden, July to September 2019. *Euro Surveill* **2019**; 24:1900603.
8. Furberg M. Towards the limits—climate change aspects of life and health in Northern Sweden: studies of tularemia and regional experiences of changes in the environment. Umeå, Sweden: Umeå University Medical Dissertations, **2016**. Available at: <https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-126949>.
9. Eliasson H, Bäck E. Tularaemia in an emergent area in Sweden: an analysis of 234 cases in five years. *Scand J Infect Dis* **2007**; 39:880–9.
10. Ma Y, Vigouroux G, Kalantari Z, Goldenberg R, Destouni G. Implications of projected hydroclimatic change for tularemia outbreaks in high-risk areas across Sweden. *Int J Environ Res Public Health* **2020**; 17:6786.
11. Desvars A, Furberg M, Hjertqvist M, et al. Epidemiology and ecology of tularemia in Sweden, 1984–2012. *Emerging Infect Dis* **2015**; 21:32–9.
12. Seiwald S, Simeon A, Hofer E, Weiss G, Bellmann-Weiler R. Tularemia goes west: epidemiology of an emerging infection in Austria. *Microorganisms* **2020**; 8:1597.
13. Maurin M, Pelloux I, Brion JP, Del Bano JN, Picard A. Human tularemia in France, 2006–2010. *Clin Infect Dis* **2011**; 53:e133–41.
14. Faber M, Heuner K, Jacob D, Grunow R. Tularemia in Germany—a re-emerging zoonosis. *Front Cell Infect Microbiol* **2018**; 8:40.
15. Jones RM, Nicas M, Hubbard A, Sylvester MD, Reingold A. The infectious dose of *Francisella tularensis* (tularemia). *Applied Biosafety* **2005**; 10:227–39.
16. Tärnvik A, Berglund L. Tularaemia. *Eur Respir J* **2003**; 21:361–73.
17. Caspar Y, Maurin M. *Francisella tularensis* susceptibility to antibiotics: a comprehensive review of the data obtained in vitro and in animal models. *Front Cell Infect Microbiol* **2017**; 7:122.
18. World Health Organization. WHO Guidelines on tularaemia. Geneva, Switzerland: WHO Press, World Health Organization, **2007**.
19. Johansson A, Berglund L, Sjöstedt A, Tärnvik A. Ciprofloxacin for treatment of tularemia. *Clin Infect Dis* **2001**; 33:267–8.
20. Williams MS, Baker MR, Guina T, et al. Retrospective analysis of pneumonic tularemia in Operation Whitecoat human subjects: disease progression and tetracycline efficacy. *Front Med* **2019**; 6:229.
21. Hepburn MJ, Simpson AJ. Tularemia: current diagnosis and treatment options. *Expert Rev Anti Infective Ther* **2008**; 6:231–40.
22. Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. *Ann N Y Acad Sci* **2007**; 1105:378–404.
23. Statistics Sweden. Population statistics—Quarter 2, 2023. Available at: <https://www.scb.se/en/finding-statistics/statistics-by-subject-area/population/population-composition/population-statistics/pog/tables-and-graphs/population-statistics-month-quarter-half-year/population-statistics-quarter-2-2023/>. Accessed 8 October 2023.
24. Kiliç S, Çelebi B, Yeşilyurt M. Evaluation of a commercial immunochromatographic assay for the serologic diagnosis of tularemia. *Diagn Microbiol Infect Dis* **2012**; 74:1–5.
25. Lindgren H, Eklund J, Eneslätt K, Sjöstedt A. Kinetics of the serological response up to one year after tularemia. *Front Cell Infect Microbiol* **2022**; 12:1072703.
26. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. *Source Code Biol Med* **2008**; 3:17.
27. Penn RL, Kinasewitz GT. Factors associated with a poor outcome in tularemia. *Arch Intern Med* **1987**; 147:265–8.
28. Dahlstrand S, Ringertz O, Zetterberg B. Airborne tularemia in Sweden. *Scand J Infect Dis* **1971**; 3:7–16.
29. Eliasson H, Lindbäck J, Nuorti JP, Arneborn M, Giesecke J, Tegnell A. The 2000 tularemia outbreak: a case-control study of risk factors in disease-endemic and emergent areas, Sweden. *Emerging Infect Dis* **2002**; 8:956–60.
30. Svensson K, Bäck E, Eliasson H, et al. Landscape epidemiology of tularemia outbreaks in Sweden. *Emerging Infect Dis* **2009**; 15:1937–47.
31. Christenson B. An outbreak of tularemia in the northern part of central Sweden. *Scand J Infect Dis* **1984**; 16:285–90.
32. Kravdal A, Stubhaug ØO, Wågo AG, et al. Pulmonary tularaemia: a differential diagnosis to lung cancer. *ERJ Open Res* **2020**; 6:00093-2019.
33. Şenel E, Satılmış Ö, Acar B. Dermatologic manifestations of tularemia: a study of 151 cases in the mid-Anatolian region of Turkey. *Int J Dermatol* **2015**; 54:e33–7.
34. Polat M, Karapınar T, Sırmatel F. Dermatological aspects of tularaemia: a study of 168 cases. *Clin Exp Dermatol* **2018**; 43:770–4.
35. Syrjälä H, Karvonen J, Salminen A. Skin manifestations of tularemia: a study of 88 cases in northern Finland during 16 years (1967–1983). *Acta Dermatol Venereologica* **1984**; 64:513–6.
36. Jounio U, Renko M, Uhari M. An outbreak of holarctica-type tularemia in pediatric patients. *Pediatr Infect Dis J* **2010**; 29:160–2.
37. Syrjälä H. Peripheral blood leukocyte counts, erythrocyte sedimentation rate and C-reactive protein in tularemia caused by the type B strain of *Francisella tularensis*. *Infection* **1986**; 14:51–4.
38. Wetzstein N, Kärcher I, Küpper-Tetzel CP, et al. Clinical characteristics in a sentinel case as well as in a cluster of tularemia patients associated with grape harvest. *Int J Infect Dis* **2019**; 84:116–20.
39. Weber IB, Turabelidze G, Patrick S, Griffith KS, Kugeler KJ, Mead PS. Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases. *Clin Infect Dis* **2012**; 55:1283–90.
40. Schöbi N, Agyeman PKA, Duppenhaler A, et al. Pediatric tularemia—a case series from a single center in Switzerland. *Open Forum Infect Dis* **2022**; 9:ofac292.

CONFIDENCE IN DOVATO ACROSS TREATMENT SETTINGS⁴⁻⁹

Treatment-naïve resistance rates, with up to **3 years of evidence**⁵⁻⁷

0%
(n=0/1,885)^{*4}
REAL-WORLD EVIDENCE

0.1%
(n=1/953)^{**1,1,5,5-7}
RANDOMISED CONTROLLED TRIALS

Treatment-experienced resistance rates, with up to **5 years of evidence**¹⁻³

0.03%
(n=10/35,888)^{*4}
REAL-WORLD EVIDENCE

0%
(n=0/615)^{†1,5,8,9}
RANDOMISED CONTROLLED TRIALS

>300,000 PEOPLE LIVING WITH HIV HAVE BEEN TREATED WITH DOVATO GLOBALLY¹⁰

DOVATO is supported by a wealth of evidence, with the outcomes of **>40,000** people living with HIV captured within clinical trials and real-world evidence, including those with:^{4-9,11,12}



NO PRIOR TREATMENT EXPERIENCE¹³



NO BASELINE RESISTANCE TESTING¹³




HIGH BASELINE VIRAL LOAD
(>100,000 copies/mL and even >1M copies/mL)^{6,13}



LOW CD4 + COUNT
(≤200 cells/mm³)¹³

■ Patients from phase III RCTs

■ Patients from unique real-world cohorts



IS IT TIME TO RECONSIDER THE VALUE OF THE 2ND NRTI?

LEARN MORE

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.¹³

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221441

REFERENCES

- Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
- Taramasso L et al. AIDS Patient Care STDS 2021; 35(9): 342-353.
- Ciccullo A et al. JAIDS 2021; 88(3): 234-237.
- ViiV Healthcare. Data on File. REF-223795. 2024.
- Cahn P et al. AIDS 2022; 36(1): 39-48.
- Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
- Cordova E et al. Poster presented at 12th IAS Conference on HIV Science. 23-26 July 2023. Brisbane, Australia. TUPEB02.
- De Wit S et al. Slides presented at HIV Glasgow. 23-26 October 2022. Virtual and Glasgow, UK. M041.
- Llibre J et al. Clin Infect Dis 2023; 76(4): 720-729.
- ViiV Healthcare. Data on File. REF-220949. 2024.
- Rolle C et al. Poster presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1603.
- Slim J et al. Abstract presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1593.
- DOVATO. Summary of Product Characteristics. June 2023.

PRESCRIBING INFORMATION

[Dovato Prescribing Information](#)

[Legal Notices](#)

[Privacy Policy](#)

[Contact Us](#)

ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, London, UK.

ViiV trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Non-ViiV trademarks are owned by or licensed to their respective owners or licensors.

©2024 ViiV Healthcare group of companies or its licensor. All rights reserved.

Intended for healthcare professionals only.

ABBREVIATIONS

3TC, lamivudine; **CD4**, cluster of differentiation 4; **DTG**, dolutegravir; **FDA**, United States Food and Drug Administration; **FTC**, emtricitabine; **HIV**, human immunodeficiency virus; **ITT-E**, intention-to-treat exposed; **NRTI**, nucleoside/nucleotide reverse transcriptase inhibitor; **RCT**, randomised controlled trial; **RNA**, ribonucleic acid; **TAF**, tenofovir alafenamide fumarate; **TDF**, tenofovir disoproxil fumarate; **XTC**, emtricitabine.

FOOTNOTES

*Data extracted from a systematic literature review of DTG+3TC real-world evidence. Overlap between cohorts cannot be fully excluded.

**The reported rate reflects the sum-total of resistance cases calculated from GEMINI I and II (n=1/716, through 144 weeks), STAT (n=0/131, through 52 weeks), and D2ARLING (n=0/106, through 24 weeks).⁵⁻⁷

†GEMINI I and II are two identical 148-week, phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority, controlled clinical trials testing the efficacy of DTG/3TC in treatment-naïve patients. Participants with screening HIV-1 RNA ≤500,000 copies/mL were randomised 1:1 to once-daily DTG/3TC (n=716, pooled) or DTG + TDF/FTC (n=717, pooled). The primary endpoint of each GEMINI study was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).¹³

‡STAT is a phase IIIb, open-label, 48-week, single-arm pilot study evaluating the feasibility, efficacy, and safety of DTG/3TC in 131 newly diagnosed HIV-1 infected adults as a first line regimen. The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 24.⁶

§D2ARLING is a randomised, open-label, phase IV study designed to assess the efficacy and safety of DTG/3TC in treatment-naïve people with HIV with no available baseline HIV-1 resistance testing. Participants were randomised in a 1:1 ratio to receive DTG/3TC (n=106) or DTG + TDF/XTC (n=108). The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48.⁷ Results at week 24 of the study.

|| The reported rate reflects the sum-total of resistance cases calculated from TANGO (n=0/369, through 196 weeks) and SALSA (n=0/246, through 48 weeks).^{8,9}

¶TANGO is a randomised, open-label, trial testing the efficacy of DOVATO in virologically suppressed patients. Participants were randomised in a 1:1 ratio to receive DOVATO (n=369) or continue with TAF-containing regimens (n=372) for up to 200 weeks. At Week 148, 298 of those on TAF-based regimens switched to DOVATO. The primary efficacy endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL (virologic non-response) as per the FDA Snapshot category at Week 48 (adjusted for randomisation stratification factor).^{8,13}

#SALSA is a phase III, randomised, open-label, non-inferiority clinical trial evaluating the efficacy and safety of switching to DTG/3TC compared with continuing current antiretroviral regimens in virologically suppressed adults with HIV. Eligible participants were randomised 1:1 to switch to once-daily DTG/3TC (n=246) or continue current antiretroviral regimens (n=247). The primary endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).⁹